MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.349
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV